Stifel raised the firm’s price target on Glaukos (GKOS) to $153 from $145 and keeps a Buy rating on the shares. The firm’s tracker of iDose-trained surgeons showed a re-acceleration in new doctors in November, giving Stifel increased confidence in upside to its $100M 2025 iDose sales estimate, the analyst tells investors. The firm continues to believe more-comprehensive Medicare Administrative Contractor reimbursement progress in the next few quarters can drive a further iDose revenue acceleration by mid-2025, the analyst added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos downgraded to Underweight from Equal Weight at Morgan Stanley
- Glaukos price target raised to $149 from $140 at BTIG
- Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval
- Glaukos price target raised to $140 from $139 at BTIG
- Glaukos price target raised to $145 from $135 at Wells Fargo